New pill plus chemo takes on deadly pancreatic cancer in huge trial

NCT ID NCT07491445

Recruiting now Disease control Sponsor: Revolution Medicines, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This phase 3 trial tests a new drug called daraxonrasib, taken as a pill, either alone or with standard chemotherapy, against chemotherapy alone for people with metastatic pancreatic cancer. About 900 adults with confirmed pancreatic cancer that has spread will be randomly assigned to one of three groups. The goal is to see if the new drug helps people live longer or keeps the cancer from growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: daraxonrasib (a RAS inhibitor drug taken as pills), gemcitabine (chemo given by IV), nab-paclitaxel (chemo given by IV)
What this could lead to: If it works, this could offer a new first-line treatment option for people with metastatic pancreatic cancer, potentially extending life or slowing tumor growth.
What could go wrong: This is a large phase 3 trial, but the drug is still investigational. It may not improve outcomes over standard chemo, and side effects from the combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic adenosquamous carcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC ADENOCARCINOMA PANCREATIC ADENOCARCINOMA METASTATIC PANCREATIC ADENOSQUAMOUS CARCINOMA PANCREATIC CANCER PANCREATIC CANCER METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) PDAC PDAC - PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Calvary Mater Newcastle
RECRUITING

Waratah, New South Wales, 2298, Australia
Cancer Institute Hospital - Japan Foundation for Cancer Research
RECRUITING

Koto-Ku, Tokyo, 135-8550, Japan
Comprehensive Cancer Centers of Nevada
RECRUITING

Henderson, Nevada, 89052, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
H Lee Moffitt Cancer Center and Research Institute
RECRUITING

Tampa, Florida, 33612, United States
Honor Health Research Institute
RECRUITING

Scottsdale, Arizona, 85258, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
RECRUITING

Baltimore, Maryland, 21287, United States

Contact Email: •••••@•••••
Kanagawa Cancer Canter
RECRUITING

Kanagawa, 241-0815, Japan
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact Email: •••••@•••••
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
NHO Kyushu Cancer Center
RECRUITING

Fukuoka, 811-1395, Japan
National Cancer Center - East
RECRUITING

Kashiwa, Chiba, 277-8577, Japan
SCRI - Texas Oncology Dallas
RECRUITING

Dallas, Texas, 95246, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Taylor Cancer Research Center
RECRUITING

Maumee, Ohio, 43537, United States
University of Cincinnati Cancer Center
RECRUITING

Cincinnati, Ohio, 45219, United States
Virginia Cancer Specialists
RECRUITING

Fairfax, Virginia, 22031, United States
Virginia Mason Medical Center
RECRUITING

Seattle, Washington, 98101, United States
Wakayama Medical University Hospital
RECRUITING

Wakayama, 641-8510, Japan
Yamaguchi University Hospital
RECRUITING

Yamaguchi, 755-8505, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.